Cadrenal Therapeutics Inc... (CVKD)
NASDAQ: CVKD
· Real-Time Price · USD
16.21
-0.21 (-1.28%)
At close: May 01, 2025, 3:57 PM
16.94
4.50%
After-hours: May 01, 2025, 06:22 PM EDT
-1.28% (1D)
| Bid | 16.5 |
| Market Cap | 31.45M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.65M |
| EPS (ttm) | -8.73 |
| PE Ratio (ttm) | -1.86 |
| Forward PE | -7.3 |
| Analyst | Strong Buy |
| Ask | 16.95 |
| Volume | 33,056 |
| Avg. Volume (20D) | 32,293 |
| Open | 16.35 |
| Previous Close | 16.42 |
| Day's Range | 16.11 - 16.91 |
| 52-Week Range | 5.70 - 22.90 |
| Beta | 1.46 |
About CVKD
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida....
Industry Biotechnology
Sector Healthcare
IPO Date Jan 20, 2023
Employees 4
Stock Exchange NASDAQ
Ticker Symbol CVKD
Website https://www.cadrenal.com
Analyst Forecast
According to 1 analyst ratings, the average rating for CVKD stock is "Strong Buy." The 12-month stock price forecast is $32, which is an increase of 97.41% from the latest price.
Stock Forecasts6 months ago
+17.97%
Cadrenal Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
